Jagsonpal Pharmaceuticals has released the voting results for its 47th Annual General Meeting (AGM) held on September 18, 2026. The company confirmed that all five resolutions proposed during the meeting were passed with substantial shareholder support.

The AGM was conducted via Video Conference/Other Audio Visual Means (VC/OAVM). Manish Gupta, Managing Director, chaired the session in the absence of Harsha Raghavan, Non-Executive Director and Chairperson. Ayush Khandelwal & Associates served as the Scrutinizer for the e-voting process.

Voting Participation

The record date for the meeting was September 11, 2026, with a total of 26,852 shareholders on record. While no shareholders attended physically or via proxy, participation through video conferencing was recorded.

Remote e-voting commenced on September 14, 2026, and concluded on September 17, 2026. The total votes polled across all resolutions ranged between 46.2 million and 49.2 million, representing approximately 70% to 75% of outstanding shares.

Key Resolutions Passed

Shareholders transacted both ordinary and special business items. The resolutions included the adoption of financial statements, dividend declaration, director appointments, and auditor ratification.

Prithpal Singh Kochar, who retires by rotation, was eligible and offered himself for reappointment. The resolution received 99.99% support on votes polled. Notably, votes cast by Mr. Rajpal Singh Kochhar, a relative of Mr. Prithpal Singh Kochhar, were declared invalid due to interest in the matter, totaling 3,030,400 shares.

The company also ratified the remuneration payable to Kirit Mehta & CO LLP, Cost Accountants, for the financial year ending March 31, 2027. This resolution saw 99.98% support, with minimal opposition from non-institutional public shareholders.

Governance Updates

A significant governance change occurred with the special resolution to appoint Anil Kumar Matai (DIN: 03122685) as an Independent Director. This appointment strengthens the board’s independent oversight capabilities and was approved with 99.99% of votes in favor.

The detailed voting results and Scrutinizer’s Report have been disseminated to stock exchanges and placed on the company’s website.

Jagsonpal Pharmaceuticals will hold its 47th Annual General Meeting on September 18, 2026, to approve a 200% dividend payout for FY26. The pharmaceutical firm reported a 19% year-on-year rise in operating profit after tax to ₹446 crore, driven by disciplined cost management and portfolio optimization.

The Board has recommended a dividend of ₹4 per equity share, comprising a ₹2.50 final dividend and a ₹1.50 special dividend. This follows a successful ₹40 crore share buyback executed in May 2026 at a premium of approximately 40% over the market price.

Financial Performance

Revenue from operations grew by 6.9% to ₹2,872 crore in FY26, up from ₹2,687 crore in the previous fiscal year. Operating EBITDA stood at ₹609 crore with a margin of 21.2%, reflecting a slight moderation from the 21.5% recorded in FY25 despite higher revenues.

Profit before tax increased to ₹596 crore from ₹502 crore in FY25. However, reported profit after tax was ₹431 crore, lower than the ₹554 crore in FY25, primarily due to exceptional items including an impact of newly notified labour codes amounting to ₹21 crore.

Strategic Developments

Jagsonpal acquired an 85% equity stake in Aequitas Healthcare Private Limited in July 2026 for ₹20.8 crore, marking its entry into the hospital segment. Aequitas generated revenues of ₹53 crore in FY26 and brings established relationships with leading hospital chains.

The company also highlighted strong brand performance, with its top 10 brands contributing 58% of total revenue. Indocap emerged as the first brand to cross ₹50 crore in sales, reinforcing leadership in pain management therapies.

What the Numbers Show

The divergence between operating profit growth (19%) and revenue growth (7%) indicates significant operating leverage. Additionally, free cash flow conversion remained robust at nearly 100% of EBITDA, enabling substantial shareholder returns through dividends and buybacks while maintaining a net cash position of ₹1,907 crore.